166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy

Journal of Nuclear Medicine

Volumn 47, Issue 3, 2006, Pages 534-542

  Breitz, Hazel B ^a   Wendt III, Richard E ^b   Stabin, Michael S ^c   Shen, Sui ^d   Erwin, William D ^b   Rajendran, Joseph G ^e   Eary, Janet F ^f   Durack, Lawrence ^e   Delpassand, Ebrahim ^b   Martin, William ^c   Meredith, Ruby F ^d  

^a Poniard Pharmaceuticals Inc   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f NONE

Author keywords

166Ho DOTMP; Dosimetry; Radiotherapeutic; Skeletal targeted radiotherapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAMETHYLENEPHOSPHONATE HO 166; HOLMIUM; HOLMIUM 166; MELPHALAN; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAKIS(METHYLENEPHOSPHONIC ACID); 1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAKIS(METHYLENEPHOSPHONIC ACID); DIAGNOSTIC AGENT; ORGANOPHOSPHORUS COMPOUND; RADIOISOTOPE;

ADULT; AGED; ARTICLE; BLADDER; BONE; BONE MARROW; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSIMETRY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TISSUE LEVEL; DRUG UPTAKE; FEMALE; HUMAN; ISOTOPE LABELING; KIDNEY CLEARANCE; KIDNEY TUBULE ABSORPTION; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; RADIATION DOSE; SCINTILLATION CAMERA; URINARY EXCRETION; BODY BURDEN; BONE TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; RADIOTHERAPY; RELATIVE BIOLOGIC EFFECTIVENESS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; WHOLE BODY COUNTING;

AGED; BODY BURDEN; BONE NEOPLASMS; FEMALE; HOLMIUM; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; ORGANOPHOSPHORUS COMPOUNDS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RELATIVE BIOLOGICAL EFFECTIVENESS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; WHOLE-BODY COUNTING;

EID: 33645961343     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Child AH. High dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875-1883.
2. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase I/II trials. Blood. 2003;102:2684-2691.
3. Bayouth JE, Macey DJ, Kasi LP, et al. Pharmacokinetics, dosimetry and toxicity of holmium-166 DOTMP for bone marrow ablation in multiple myeloma. J Nucl Med. 1995;36:730-737.
4. 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation. J Nucl Med. 2002;43:1383-1390.
5. Loevinger RL, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculations. Reston, VA: Society of Nuclear Medicine; 1999:5-6.
6. International Commission on Radiological Protection. ICRP Publication 53: Radiation Dose to Patients from Radiopharmaceuticals. Elmsford, NY: Pergamon Press; 1987:18-19.
7. 166Ho-DOTMP. Cancer Biother Radiopharm. 2003;18:225-230.
8. Foster D, Barrett P. Developing and testing integrated multicompartment models to describe a single-input multiple-output study using the SAAM II software system. In: Proceedings of the Sixth International Radiopharmaceutical Dosimetry Symposium. Oak Ridge, TN: Oak Ridge Institute for Science and Education; 1999:577-599.
9. Ogawa K, Ichihara T, Kubo A. Accurate scatter correction in single photon emission CT. Ann Nucl Med Sci. 1994;7:145-150.
10. Ogawa K, Harata Y, Ichihara T, Kubo A, Hashimoto S. A practical method for position-dependent Compton-scatter correction in single photon emission CT. IEEE Trans Med Imaging. 1991;10:408-412.
11. Kasiske BL, Umen AJ. The influence of age, sex, race, and body habitus on kidney weight in humans. Arch Pathol Lab Med. 1986;110:55-60.
12. Cristy M, Eckerman KF. Specific Absorbed Fractions of Energy at Various Ages from Internal Photon Sources. Oak Ridge, TN: Oak Ridge National Laboratory; 1987. ORNL report ORNL/TM-8381/V1-V7.
13. Eckerman K, Stabin M. Electron absorbed fractions and dose conversion factors for marrow and bone by skeletal regions. Health Phys. 2000;78:199-214.
14. Stabin M. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538-546.
15. International Commission on Radiological Protection. ICRP Publication 70: Basic Anatomical and Physiological Data for Use in Radiological Protection - The Skeleton. Elmsford, NY: Pergamon Press; 1997:23.
16. Breitz HB. Dosimetry in a myeloablative setting. Cancer Biother Radiopharm. 2002;17:119-128.
17. Leggett RW, Williams LR. A proposed blood circulation model for reference man. Health Phys. 1995;69:187-201.
18. Thomas SR, Stabin MG, Chen CT, Samaratunga RC. MIRD pamphlet no. 14 revised: a dynamic urinary bladder model for radiation dose calculations. J Nucl Med. 1999;40:102S-123S.
19. 166Ho [abstract]. J Nucl Med. 2003;44(suppl):139P.
20. Dale RG. Dose-rate effects in targeted radiotherapy. Phys Med Biol. 1996;41:1871-1884.
21. Dale R. Use of linear-quadratic model for quantifying kidney dose response in targeted radiotherapy. Cancer Biother Radiopharm. 2004;19:363-370.
22. Eary JF, Collins C, Stabin M, et al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med. 1993;34:1031-1036.
23. 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. J Nucl Med. 2003;44:953-960.
24. Turner JH, Claringbold PG, Hetherington EL, Sorby P, Martindale AA. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. J Clin Oncol. 1989;7:1926-1931.
25. Heggie J. Radiation absorbed dose calculations for samarium-153-EDTMP localized to bone. J Nucl Med. 1991;32:840-844.
26. International Commission on Radiological Protection. ICRP Publication 20: Report of the Task Group on Reference Man - Anatomical, Physiological and Metabolic Characteristics. Oxford, U.K.: Pergamon Press; 1975.
27. 166Ho-DOTMP for skeletal targeted radiotherapy for multiple myeloma. Blood. 2003;102:2684-2691.